| Angioedemas, Hereditary
Firazyr vs Sajazir
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Firazyr vs Sajazir with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSajazir has a higher rate of injection site reactions vs Firazyr based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sajazir but not Firazyr, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Firazyr
Sajazir
At A Glance
SC injection
As needed (up to 3 doses/24 hours)
Bradykinin B2 receptor antagonist
SC injection
As needed
Bradykinin B2 receptor antagonist
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 30 mg SC injection in the abdominal area; additional injections of 30 mg may be given at intervals of at least 6 hours if response is inadequate or symptoms recur; no more than 3 doses in any 24-hour period.
Angioedemas, Hereditary 30 mg SC injection in the abdominal area; additional doses at intervals of at least 6 hours if response is inadequate or symptoms recur; no more than 3 doses in 24 hours.
Contraindications
—
—
Adverse Reactions
Most common (>1%) Injection site reactions, pyrexia, transaminase increased, dizziness, rash, nausea, headache
Postmarketing Urticaria
Most common (>1%) Injection site reactions, pyrexia, transaminase increased, dizziness
Postmarketing Urticaria
Pharmacology
Bradykinin B2 receptor antagonist; icatibant competitively inhibits bradykinin from binding the B2 receptor, blocking the vasodilation, inflammation, and pain associated with bradykinin release in acute HAE attacks caused by C1-esterase-inhibitor deficiency or dysfunction.
Icatibant is a competitive antagonist selective for the bradykinin B2 receptor; by blocking bradykinin binding to the B2 receptor, it treats the localized swelling, inflammation, and pain of acute HAE attacks caused by C1-esterase-inhibitor deficiency-driven excess bradykinin production.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Firazyr
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (8/12) · Qty limit (9/12)
Sajazir
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Firazyr
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (2/8)
Sajazir
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Firazyr
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Sajazir
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FirazyrView full Firazyr profile
SajazirView full Sajazir profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.